IIPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IIPR is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is technically stable to mildly bullish in the short term, but the current setup does not offer a compelling long-term entry because fundamentals are still deteriorating and analyst sentiment remains mixed to cautious. With no recent bullish news or insider/congress buying and earnings due soon, the best call is to hold rather than buy aggressively at this price.
The price is in pre-market at 54.8, slightly above the stated current price of 54.25 and near the pivot level of 54.777. Trend structure is constructive: SMA_5 > SMA_20 > SMA_200, which signals a bullish moving-average stack. MACD histogram is positive at 0.227, though it is contracting, suggesting momentum is still positive but losing strength. RSI_6 at 52.394 is neutral, so the stock is neither overbought nor oversold. Key nearby support is 52.582, with resistance at 56.972 and 58.328. Overall, the chart shows a modest uptrend, but not a high-conviction breakout setup.
["Analyst price target was raised to $55 by Alliance Global, suggesting some improved visibility after the Q4 report.", "Piper Sandler noted green shoots in cannabis and re-awakening life science leasing in Boston.", "Technical trend is still constructive with bullish moving averages and positive MACD histogram.", "Current price is close to analyst target range, which may support near-term stabilization."]
["No news in the recent week, so there is no fresh catalyst driving the stock higher.", "Q4 2025 financials weakened: revenue fell 13.14% YoY, net income fell 22.95% YoY, EPS fell 22.63% YoY, and gross margin declined 9.09% YoY.", "Options sentiment is bearish, with put-call ratios above 1 on both open interest and volume.", "Analyst coverage remains cautious overall, with one Underweight rating still in place and only a recent move to Neutral from Sell.", "Pattern-based trend estimate suggests downside over the next week and month.", "No recent insider buying, no significant hedge fund accumulation, and no congress trading activity."]
In 2025/Q4, financial performance was weaker across the board. Revenue declined to $66.66M, down 13.14% YoY. Net income dropped 22.95% YoY to $29.96M. EPS fell 22.63% YoY to $1.06, and gross margin also decreased to 60.22%, down 9.09% YoY. For a long-term investor, this is not yet a clear growth acceleration story; the latest quarter shows contraction rather than improving momentum.
Analyst sentiment has improved slightly but remains cautious. Compass Point upgraded IIPR to Neutral from Sell with a $45 target. Alliance Global raised its target to $55 from $50 and kept a Neutral rating, citing better visibility into rent recovery on defaulted assets. Piper Sandler raised its target slightly to $45 from $44 but kept an Underweight rating, emphasizing unclear recovery slopes and ongoing legacy tenant credit issues. Overall, Wall Street is mixed-to-bearish: a few incremental positives, but no broad bullish consensus.
